Vitamin D3 Dissolution Test: A Lab Walkthrough for Tablets and Softgels (USP <2040>)

About this lab walkthrough

Method walkthrough, not a batch report. This post follows a vitamin D3 tablet or softgel through the release-testing steps a lab works through. It does not report results from an FRL product: every number below comes from the published studies cited. The compendial detail is given only as far as the public sources confirm; always check the current USP–NF text before writing a specification. This is educational, not regulatory advice.

What a vitamin D3 dissolution test shows

A vitamin D3 dissolution test measures how much cholecalciferol a tablet or capsule releases into a defined medium over time. It sits alongside two simpler performance tests: disintegration, which asks whether the unit breaks apart within a set time, and, for softgels, a rupture test, which asks whether the shell opens.

USP general chapter <2040> provides the procedures used to check compliance with the disintegration and dissolution standards for dietary supplements where an individual monograph states them^[1]. It includes a rupture test for soft-shell capsules, which has been compared with the conventional disintegration test for softgels^[7]. USP <1711> is an informational chapter on developing performance tests for oral dosage forms that are not covered by <701> Disintegration, <711> Dissolution, <1092> The Dissolution Procedure: Development and Validation, or <2040>^[2].

A passing result shows that the unit releases its vitamin D3 under test conditions. It does not show how much is absorbed.

Step 1: Raw material and dosage form

Vitamin D3 is practically insoluble in water, and in one study a cyclodextrin complex of cholecalciferol degraded in the liquid phase during long-term storage, so the authors spray-dried it into a powder^[5]. Solubility and stability drive the choice of form: an oil solution for softgels, a powder or beadlet for tablets and capsules, or a solid dispersion. Each raw material is checked for identity, potency and compatibility with the planned excipients before a prototype is made.

Step 2: Building prototypes

Prototypes are built to meet release and content targets at the same time. In one study, a solid self-microemulsifying system of vitamin D3 adsorbed on a magnesium aluminometasilicate carrier (Neusilin US2) was compressed into tablets that met pharmacopeial quality-control tests, and the SMEDDS forms released more vitamin D3 in vitro than the unprocessed vitamin^[4].

A separate study used eggshell powder as a tablet filler and tested the tablets for weight variation, content uniformity, hardness, friability, disintegration and dissolution^[3]. The same battery is a sensible first screen for any new vitamin D3 tablet prototype.

Step 3: Disintegration, rupture and dissolution tests

Tablets and hard capsules

Disintegration is the quick screen: a unit that does not break apart will not release its active. Dissolution then measures how much vitamin D3 is released and dissolved at set time points. In the eggshell-filler study, all formulations released 99.29–101.05% of their vitamin D3 by 90 minutes^[3].

Softgels

For a softgel, shell opening is the first event in release, so <2040> applies a rupture test to soft-shell capsules. One comparison of aged softgels found that the rupture test and the conventional disintegration test did not give equivalent results, so the choice of test matters^[7].

Apparatus, medium and limits

Apparatus, medium volume, rotation speed, time points and acceptance criteria are set by the chapter and monograph in force. The full USP text is behind a paywall and is not reproduced here; confirm the current requirements in USP–NF before writing a specification.

Step 4: Developing and validating the dissolution method

For a fat-soluble, practically insoluble vitamin, the medium is the hard decision. FDA’s dissolution guidance for drugs, a useful reference for supplement methods, recommends a surfactant such as sodium lauryl sulfate for water-insoluble products and says the need for, and amount of, surfactant should be justified^[8].

Method development screens media and agitation until the method discriminates between good and poor formulations. Validation then shows that the assay of dissolved vitamin D3 is accurate, precise and specific at the concentrations reached in the vessel, and the medium is fixed in the written method. A dissolution method that cannot tell formulations apart is not useful for release.

Step 5: Quality checks on the finished unit

Before dissolution, each prototype is checked for appearance, weight variation, hardness, friability and content uniformity. Content uniformity matters because a batch that passes dissolution on average can still contain low units. In the eggshell-filler study, high-dose tablets labelled at 50,000 IU contained 98.77–102.35% of the label amount^[3].

Step 6: Re-testing on stability samples

Dissolution is repeated on stability samples, because release can drift as tablets harden or softgel shells age. Assay results from the same samples show how much vitamin D3 is lost; one research tablet reported a T₉₀ of 28.12 months^[4]. Those assay results feed the overage decision explained in our vitamin D overage guide, and the study design follows the same logic as our guide to real-time and accelerated shelf-life testing.

Step 7: Scale-up checks

Optimisation adjusts excipients, particle size or carrier until release and content hold across batch sizes. At scale, the vitamin D3 dissolution test is run on pilot batches to confirm that the bench result survives the larger process. A release profile that changes between bench and pilot scale is a signal to revisit blending, compression force or capsule fill. Our scale-up worked example shows how a recipe moves from bench to pilot plant.

Quality records under 21 CFR Part 111

US dietary supplement makers must establish product specifications for identity, purity, strength and composition, and test to determine whether they are met^[6]. Reserve samples are kept for 1 year past the shelf-life date where shelf-life dating is used, or for 2 years from distribution of the last batch^[6]. A dissolution or disintegration test belongs in the specification when a monograph requires it or when data show it is needed to control release. Our FDA vitamin D supplement rules guide covers the labelling side.

Key technical takeaways

• Choose the dosage form for the dose and the release you need: oil-filled softgel, powder or beadlet tablet, or solid dispersion.
• Use disintegration (tablets) or the rupture test (softgels) as the first screen, then dissolution for release.
• Justify the medium for a practically insoluble vitamin, and validate a method that discriminates between formulations.
• Repeat release and assay testing on stability samples, and keep the records Part 111 requires.

Formulator’s note. Dissolution is not bioavailability. A passing result shows the unit releases its vitamin D3 under test conditions; absorption claims need human data. Our VITAL trial explainer shows where the clinical evidence for vitamin D stands.

For brands &amp; formulators

Food Research Lab supports US supplement brands from Chennai, India. Our nutraceutical team designs the vitamin D3 formulation, plans the release-testing programme and sets specifications with you. Disintegration, rupture, dissolution and assay testing are run or arranged through accredited partner laboratories. For a related release study, see our chewing gum active-release lab diary.

See our nutraceutical product development service or regulatory and scientific research, or contact us with your formula and dosage form.

In this series

• The VITAL trial explained: what the vitamin D results mean for US supplement makers.
• FDA rules for vitamin D supplements: Supplement Facts, mcg and IU, tolerances and claims.
• Vitamin D overage: setting a label claim that survives shelf life (series guide).
• Vitamin D3 dissolution testing: how release is checked on tablets and softgels (you are here).
• Vitamin D3 supplement development: a worked example from formula to label claim.
• Nutraceutical product development: take your vitamin D3 product from brief to launch.

1. United States Pharmacopeia. (2018). General chapter <2040> Disintegration and dissolution of dietary supplements. In USP–NF. United States Pharmacopeial Convention. https://doi.org/10.31003/USPNF_M99970_04_01 (cited for the chapter’s scope; it also contains the rupture test for soft-shell capsules; full text by subscription)
2. United States Pharmacopeia. (2020). General chapter <1711> Oral dosage forms: Performance tests. In USP–NF. United States Pharmacopeial Convention. https://doi.org/10.31003/USPNF_M7083_02_01 (cited for the chapter’s scope and its list of related chapters <701>, <711>, <1092> and <2040>)
3. Haq, N., Ibrahim, M. A., Alsarra, I. A., Alshehri, S., Alam, P., & Shakeel, F. (2024). Utilization of waste eggshell powder as an excipient for vitamin D3 tablet preparation. ACS Omega, 9(3), 3980–3987. https://doi.org/10.1021/acsomega.3c08416 (cited for the USP test battery, 50,000 IU tablets, content 98.77–102.35% and release 99.29–101.05% at 90 minutes)
4. Dangre, P. V., Gurram, N. J., Surana, S. J., & Chalikwar, S. S. (2022). Development and optimization of vitamin D₃ solid self-microemulsifying drug delivery system: Investigation of flowability and shelf life. AAPS PharmSciTech, 23(4), 110. https://doi.org/10.1208/s12249-022-02267-z (cited for SMEDDS tablets on Neusilin US2, improved in vitro dissolution and T₉₀ of 28.12 months)
5. Wang, F., Yu, W., Popescu, C., Ibrahim, A. A., Yu, D., Pearson, R., MacKerell, A. D., Jr., & Hoag, S. W. (2022). Cholecalciferol complexation with hydroxypropyl-β-cyclodextrin (HPBCD) and its molecular dynamics simulation. Pharmaceutical Development and Technology, 27(4), 389–398. https://doi.org/10.1080/10837450.2022.2064492 (cited for vitamin D3 being practically insoluble in water and the complex degrading in the liquid phase, requiring spray drying)
6. U.S. Food and Drug Administration. (2025). 21 CFR Part 111: Current good manufacturing practice in manufacturing, packaging, labeling, or holding operations for dietary supplements (§111.70 specifications; §111.75 testing; §111.83 reserve samples). Electronic Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-111
7. Yacobucci, M., Shan, C., Huang, T., Stein, D., Zhao, F., & Chablani, L. (2014). Evaluation of dietary softgel capsules using USP<701> and USP<2040>: A comparative disintegration study [Meeting abstract, 115th AACP Annual Meeting]. American Journal of Pharmaceutical Education, 78(5), 111. https://fisherpub.sjf.edu/pharmacy_facpub/218 (cited for the <2040> rupture test and its non-equivalence with conventional disintegration for aged softgels)
8. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. (1997). Guidance for industry: Dissolution testing of immediate release solid oral dosage forms. https://www.fda.gov/media/70936/download (cited for surfactant use, e.g. sodium lauryl sulfate, for water-insoluble products and justification of its amount)